Abstract:Objective To investigate the relationships between ALP、PSA、PSAD (PSA density) and free-to-total PSA (fPSA/tPSA) ratio and osseous metastasis in prostate cancer patients,and the role of these parameters in the prediction of osseous metastasis in prostate cancer.Methods A total of 167 patients with histologically diagnosed prostate cancer in our hospital from Sep.2005 to Feb.2009 were analysed.Serum PSA levels were measured using the ROCHE Modular Analytics E170 automatic electrochemiluminescence immunoassay.Volume of prostate was estimated by abdominal ultrasound measurements using the prostate ellipse formula (0.52×length×width×height).PSAD (PSA/volume) was calculated by dividing serum PSA level by volume of prostate.ECT,CT/MRI and bone biopsy were used for diagnosis of osseous metastasis.Results Of 167 consecutive patients,104 had osseous metastasis (62.3%).ALP,PSA,fPSA and PSAD in osseous metastasis group were higher than non-osseous metastasis group,respectively (P<0.01),no significant difference existed for fPSA/tPSA between osseous metastasis group and non-osseous metastasis group (P>0.05).Osseous metastasis positive rate:PSA levels of >50 ng/ml was higher than levels of >20-50 ng/ml,>10-20 ng/ml and ≤10 ng/ml(P<0.05); ALP levels of >90 U/L was higher than levels of ≤90 U/L (P<0.05); PSAD>0.4 ng·ml-1·cm-3 was higher than PSAD≤0.4 ng·ml-1·cm-3(P<0.05).Sensitivity,specificity,positive predictive value and negative predictive value:ALP cut-off of 90 U/L were 55.77%,74.60%,78.38% and 50.54%,respectively; PSA cut-off of 50 ng/ml were 85.58%,77.78%,86.41% and 76.56%,respectively; PSAD cut-off of 0.4 ng·ml-1·cm-3 were 97.12%,38.10%,72.14% and 88.89%,respectively.PSAD cut-off of 0.4 ng·ml-1·cm-3 combined with PSA cut-off of 50 ng/ml and ALP cut-off of 90 U/L were showed the best sum of sensitivity,specificity,positive predictive value and negative predictive value,which were 100%,79.17%,91.38% and 100%,respectively.Conclusion s ALP,PSA and PSAD are valuable parameters used in prediction of osseous metastasis in prostate cancer.Although further studies are needed to determine optimal cut-off value to be used in clinical practice,PSAD cut-off of 0.4 ng·ml-1·cm-3 combined with PSA cut-off of 50 ng/ml and ALP cut-off of 90 U/L seems to be useful for the prediction of osseous metastasis in prostate cancer patients.This would be justified its utility in clinical practice reducing unnecessary ECT and CT/MRI examinations,which are relatively expensive and harmful.

Detection and Clinical Application of Bone Metabolic Markers in Prostate Cancer Patients

Clinical Value of N-MID and Β-Ctx for the Diagnosis of Bone Metastases

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Serum Bone Turnover Markers in Patients with Primary Bone Tumors.

Value of C-Telopeptide-Cross-Linked Type I Collagen, Osteocalcin, Bone-Specific Alkaline Phosphatase and Procollagen Type I N-Terminal Propeptide in the Diagnosis and Prognosis of Bone Metastasis in Patients with Malignant Tumors

[Bone Turnover Markers in the Detection of Bone Metastases in Primary Lung Cancer].

Beta-Ctx And Ctp Act As Indicators Of Skeletal Metastasis Status In Mace Patients With Non-Small Cell Bung Cancer

The Application of Radionuclide Bone Scintigraphy,Serum PSA and ALP Measurement in Diagnosis of Bone Metastasis in Prostate Cancer Patients

The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer

The diagnostic significance of tiyeⅠcollagen-cross-linked N telopeptide in bone metastasis of prostate cancer

Study on Diagnostic Value of P1NP and Β-Ctx in Bone Metastasis of Patients with Breast Cancer and the Correlation Between Them.

Usefulness of serum bone metabolic markers for the diagnosis of differentiated thyroid cancer with bone metastases

Study on the Clinical Value of Pulmonary Tumor Markers and Bone Alkafine Phosphatase Detection in Early Diagnosis of Bone Metastasis of Lung Cancer

The Value Analysis of Bone Metabolic Markers CTx, OST, BAP and PINP for Bone Metastases in Breast Cancer Patients

Relationship between ALP、PSA、PSA-based parameters and bone metastasis in PCa

Beta-CTX and ICTP Act As Indicators of Skeletal Metastasis Status in Male Patients with Non-Small Cell Lung Cancer

Clinical Significance of PSA and ECT in Diagnosis of Prostate Cancer with Bone Metastasis

The Role of procollagen type 1 amino-terminal propertied (P1NP) Cytochrome P450 (CYPs) and Osteoprotegerin (OPG) as Potential Bone function markers in Prostate Cancer Bone Metastasis

[Diagnostic Value of Bone Metabolic Markers ICTP and BAP in Lung Cancer Patients with Bone Metastases].

[Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34].

[Relationship Between Bone Markers and the Progression of Multiple Myeloma].